Michelle Mahler
Chief Medical OfficerMs. Michelle Mahlerr, M.D. is Chief Medical Officer of Compugen Ltd. from March 01, 2024. Ms. Mahle joined Compugen in October 2023 as Vice President of Clinical Development. She was the Chief Medical Officer of 1 E therapeutics Ltd. a drug development company, creating a novel class of programmable oligonucleotide therapeutics and Aummune Therapeutics Ltd. a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. She was Vice President of Clinical Development at C4 Therapeutics Inc. helping to build up the clinical development group and leading the successful submission of two INDs and initiation of Phase 1 studies. Prior to C4 Therapeutics, she worked in R&D at Janssen (now Johnson & Johnson). During her time there she gained experience in late-stage clinical development, pediatric development and global medical affairs while being a key member of the ibrutinib development team and held positions of increasing responsibility. In addition, she supported key due diligence projects including the acquisition of Momenta Pharmaceuticals Inc. by Johnson & Johnson. Prior to starting in industry in 2011, she trained at Memorial Sloan Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell. She also spent time at Columbia Presbyterian and Mount Sinai Medical Center in New York. She obtained her medical degree from University of the Witwatersrand, South Africa and is a board-certified pediatric hematologist and oncologist.
Positions
- Company NameCompugen Ltd.Stock CodeCGENPositionChief Medical OfficerColleagues
- ACAnat Cohen-DayagExecutive Chair
- EOEran OphirCEO, President & Director
- PFPierre FerreChief Operating Officer
- ZLZurit LevineSenior Vice President of Business Development
- AMAndrew Mark PardollChairman of Scientific Advisory Board
- GHGilead HalevyIndependent Director
- SSSanford S. ZweifachIndependent Director
